Jonathan Gootee1, Sarah Aurit2, Christina Curtin3, Peter Silberstein4. 1. Creighton University School of Medicine, 2500 California Plaza, Omaha, NE, 68178, USA. JonathanGootee@creighton.edu. 2. Division of Clinical Research and Evaluative Sciences, Creighton University School of Medicine, Omaha, NE, USA. 3. Creighton University School of Medicine, 2500 California Plaza, Omaha, NE, 68178, USA. 4. Division of Hematology/Oncology, Department of Internal Medicine, Creighton University Medical Center, Omaha, NE, USA.
Abstract
BACKGROUND: Dedifferentiated liposarcoma (DDLPS) is a high-grade, clinically aggressive tumor associated with low survival probabilities. Prognostic variables for DDLPS have not been previously reported in a large patient population. METHODS: A total of 3573 patients with primary DDLPS were analyzed from the National Cancer Data Base (NCDB). The 5- and 10-year survival probabilities were calculated, and the groups were compared using log-rank comparisons and multivariable Cox hazard regression analysis. Median survival was also calculated. RESULTS: Males comprised 65% of the cohort, the median age at diagnosis was 64 years of age, and 65.4% of the patients were between 51 and 75 years of age. The most common site for primary tumors is the retroperitoneum or abdomen (59.5%). Head or neck tumors had the best 5-year outcomes (86.4%) followed by extremities (67.1%), pelvis (65.8%), thorax or trunk (58.9%), and finally retroperitoneum or abdomen (42.6%). Best outcomes were noted in the 26- to 50-year-old age group (5-year survival:66.8%), < 10 cm size (5-year survival:66.1%), FNCLCC grade 1 (5-year survival:69.2%), and stage II disease (5-year survival:66.7%). Radiation therapy yielded the best 5-year and 10-year survival probabilities of 59% and 39.3%, respectively. Out of all the adjuvant therapies, the use of radiation resulted in the best 5-year survival of 63.4%. CONCLUSION: In the largest and most comprehensive study to date on DDLPS, major findings include primary site as a significant prognostic variable with age at presentation, sex, tumor stage, and type of adjuvant therapy significantly impacting overall survival.
BACKGROUND: Dedifferentiated liposarcoma (DDLPS) is a high-grade, clinically aggressive tumor associated with low survival probabilities. Prognostic variables for DDLPS have not been previously reported in a large patient population. METHODS: A total of 3573 patients with primary DDLPS were analyzed from the National Cancer Data Base (NCDB). The 5- and 10-year survival probabilities were calculated, and the groups were compared using log-rank comparisons and multivariable Cox hazard regression analysis. Median survival was also calculated. RESULTS: Males comprised 65% of the cohort, the median age at diagnosis was 64 years of age, and 65.4% of the patients were between 51 and 75 years of age. The most common site for primary tumors is the retroperitoneum or abdomen (59.5%). Head or neck tumors had the best 5-year outcomes (86.4%) followed by extremities (67.1%), pelvis (65.8%), thorax or trunk (58.9%), and finally retroperitoneum or abdomen (42.6%). Best outcomes were noted in the 26- to 50-year-old age group (5-year survival:66.8%), < 10 cm size (5-year survival:66.1%), FNCLCC grade 1 (5-year survival:69.2%), and stage II disease (5-year survival:66.7%). Radiation therapy yielded the best 5-year and 10-year survival probabilities of 59% and 39.3%, respectively. Out of all the adjuvant therapies, the use of radiation resulted in the best 5-year survival of 63.4%. CONCLUSION: In the largest and most comprehensive study to date on DDLPS, major findings include primary site as a significant prognostic variable with age at presentation, sex, tumor stage, and type of adjuvant therapy significantly impacting overall survival.
Authors: A Le Cesne; M Ouali; M G Leahy; A Santoro; H J Hoekstra; P Hohenberger; F Van Coevorden; P Rutkowski; R Van Hoesel; J Verweij; S Bonvalot; W P Steward; A Gronchi; P C W Hogendoorn; S Litiere; S Marreaud; J Y Blay; W T A Van Der Graaf Journal: Ann Oncol Date: 2014-10-06 Impact factor: 32.976
Authors: S H Tirumani; H Tirumani; J P Jagannathan; A B Shinagare; J L Hornick; N H Ramaiya; A J Wagner Journal: Eur J Surg Oncol Date: 2015-01-24 Impact factor: 4.424
Authors: Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee Journal: Lancet Date: 2002-06-29 Impact factor: 79.321
Authors: Chiara Mussi; Paola Collini; Rosalba Miceli; Marta Barisella; Luigi Mariani; Marco Fiore; Paolo G Casali; Alessandro Gronchi Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Katarina Engström; Peter Bergh; Pelle Gustafson; Ragnar Hultborn; Helena Johansson; Rickard Löfvenberg; Olga Zaikova; Clement Trovik; Ola Wahlström; Henrik C F Bauer Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Carolin Knebel; Ulrich Lenze; Florian Pohlig; Florian Lenze; Norbert Harrasser; Christian Suren; Jonathan Breitenbach; Hans Rechl; Rüdiger von Eisenhart-Rothe; Heinrich M L Mühlhofer Journal: BMC Cancer Date: 2017-06-12 Impact factor: 4.430
Authors: J A Livingston; D Bugano; A Barbo; H Lin; J E Madewell; W L Wang; A J Lazar; W W Tseng; C L Roland; B W Feig; R Pollock; A P Conley; R S Benjamin; S Patel; N Somaiah Journal: Sci Rep Date: 2017-09-19 Impact factor: 4.379